共 50 条
- [11] ANALYSIS OF ORPHAN DRUGS REIMBURSEMENT IN MAJOR EUROPEAN HTA AGENCIES [J]. VALUE IN HEALTH, 2016, 19 (07) : A602 - A602
- [14] REIMBURSEMENT OF ORPHAN DRUGS: WHAT IS THE DIFFERENCE? [J]. VALUE IN HEALTH, 2012, 15 (07) : A311 - A311
- [15] THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE [J]. VALUE IN HEALTH, 2008, 11 (06) : A375 - A376
- [16] ULTRA ORPHAN AND CANCER DRUG PRICING TRENDS IN THE US AND THE UK [J]. VALUE IN HEALTH, 2015, 18 (07) : A547 - A547
- [17] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS [J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
- [19] Trends in individual reimbursement of orphan drugs in Latvia in 2008-2011 [J]. 4TH INTERNATIONAL INTERDISCIPLINARY SCIENTIFIC CONFERENCE SOCIETY, HEALTH, WELFARE, 2014, 10
- [20] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact [J]. EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28